MétaCan
Menu
Back to cohort
Record W2505446618 · doi:10.1016/j.bbmt.2016.07.007

Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis

2016· article· en· W2505446618 on OpenAlexaff
Emma C. Scott, Parameswaran Hari, Manish Sharma, Jennifer Le‐Rademacher, Jiaxing Huang, Dan T. Vogl, Muneer H. Abidi, Amer Beitinjaneh, Henry C. Fung, Siddhartha Ganguly, Gerhard Hildebrandt, Leona Holmberg, Matt Kalaycio, Shaji Kumar, Robert A. Kyle, Hillard M. Lazarus, Cindy Lee, Richard T. Maziarz, Kenneth R. Meehan, Joseph Mıkhael, Taiga Nishihori, Muthalagu Ramanathan, Saad Z. Usmani, Jason Tay, David H. Vesole, Baldeep Wirk, Jean A. Yared, Bipin N. Savani, Cristina Gasparetto, Amrita Krishnan, Tomer M. Mark, Yago Nieto, Anita D’Souza

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2016
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversity of Ottawa
FundersOffice of Naval ResearchOnyx PharmaceuticalsHealth Resources and Services AdministrationOtsuka PharmaceuticalMiltenyi BiotecIncyteTelomere DiagnosticsSunesisNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationTherakosSigma-Tau PharmaceuticalsChimerixMedical College of WisconsinTakeda OncologyUniversity of MinnesotaSpectrum PharmaceuticalsNational Marrow Donor ProgramSt. Baldrick's FoundationGenentechSeattle GeneticsPharmacyclicsHealth ResearchNational Cancer InstituteGilead SciencesLeukemia and Lymphoma SocietyGenzymeAlexion PharmaceuticalsJazz PharmaceuticalsBe The Match FoundationOtsuka America PharmaceuticalAmgenNational Institute of Allergy and Infectious DiseasesRoswell Park Cancer InstituteFred Hutchinson Cancer Research CenterCelgeneGamida CellWellPointSanofi
KeywordsMedicineMultiple myelomaInternal medicineBortezomibConfidence intervalOncologyFluorescence in situ hybridizationTransplantationChromosomeGene

Abstract

fetched live from OpenAlex

Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes. We analyzed these differences among HRM versus non-HRM populations after upfront autologous hematopoietic cell transplantation (autoHCT). Between 2008 and 2012, 715 patients with multiple myeloma identified by FISH and/or cytogenetic data with upfront autoHCT were identified in the Center for International Blood and Marrow Transplant Research database. HRM was defined as del17p, t(4;14), t(14;16), hypodiploidy (<45 chromosomes excluding -Y) or chromosome 1 p and 1q abnormalities; all others were non-HRM. Among 125 HRM patients (17.5%), induction with bortezomib and immunomodulatory agents (imids) was higher compared with non-HRM (56% versus 43%, P < .001) with similar pretransplant complete response (CR) rates (14% versus 16%, P .1). At day 100 post-transplant, at least a very good partial response was 59% in HRM and 61% in non-HRM (P = .6). More HRM patients received post-transplant therapy with bortezomib and imids (26% versus 12%, P = .004). Three-year post-transplant progression-free (PFS) and overall survival (OS) rates in HRM versus non-HRM were 37% versus 49% (P < .001) and 72% versus 85% (P < .001), respectively. At 3 years, PFS for HRM patients with and without post-transplant therapy was 46% (95% confidence interval [CI], 33 to 59) versus 14% (95% CI, 4 to 29) and in non-HRM patients with and without post-transplant therapy 55% (95% CI, 49 to 62) versus 39% (95% CI, 32 to 47); rates of OS for HRM patients with and without post-transplant therapy were 81% (95% CI, 70 to 90) versus 48% (95% CI, 30 to 65) compared with 88% (95% CI, 84 to 92) and 79% (95% CI, 73 to 85) in non-HRM patients with and without post-transplant therapy, respectively. Among patients receiving post-transplant therapy, there was no difference in OS between HRM and non-HRM (P = .08). In addition to HRM, higher stage, less than a CR pretransplant, lack of post-transplant therapy, and African American race were associated with worse OS. In conclusion, we show HRM patients achieve similar day 100 post-transplant responses compared with non-HRM patients, but these responses are not sustained. Post-transplant therapy appeared to improve the poor outcomes of HRM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0020.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.002
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.250
Teacher spread0.241 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations41
Published2016
Admission routes1
Has abstractno

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207